A clinical trial of KP484
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Serdexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 02 Nov 2017 According to a KemPharm media release, this study is anticipated to be initiated in 2018.
- 02 Nov 2017 According to a KemPharm media release, Investigational New Drug (IND) application has been approved.